最新临床试验：帕博利珠单抗是否联合立体定向全身放射治疗晚期或转移性默克尔细胞癌的疗效对比

这是经美国国家癌症研究所批准的一项多中心随机对照 II期临床试验，目的是研究帕博利珠单抗在治疗已经扩散到身体其他部位的默克尔细胞癌患者时，是否联用立体定向体放射治疗的效果。使用单克隆抗体进行免疫治疗，如帕博利珠单抗，可以帮助身体的免疫系统攻击癌症，并可能干扰肿瘤细胞生长和扩散的能力。立体定向身体放射治疗是利用特殊的设备定位病人，并向肿瘤提供高精度的放射治疗。这种方法可以在较短的时间内用较少的剂量杀死肿瘤细胞，对正常组织的损伤也较小。帕博利珠单抗联用立体定向身体放射治疗可能更好地治疗默克尔细胞癌患者。

该临床试验在全美203家医院进行开展。

This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with Merkel cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving pembrolizumab with stereotactic body radiation therapy may work better in treating patients with Merkel cell cancer.

Trial IDs